查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
甲癬治療市場：按治療類型、類型、地區劃分——規模、份額、展望、機會分析，2022-2028 年
市場調查報告書
商品編碼
1181746

甲癬治療市場：按治療類型、類型、地區劃分——規模、份額、展望、機會分析，2022-2028 年

Onychomycosis Treatment Market, By Treatment Type, By Type, and By Geography - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028
出版日期: | 出版商: Coherent Market Insights | 英文 162 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

甲癬是一種真菌感染，會影響腳趾甲和手指甲，並且會影響指甲的任何部分。 藥物治療成功率高，是治療的首選。 新一代口服抗真菌藥物（伊曲康唑和特比□芬）已經取代了治療甲癬的常規療法。

市場動態

糖尿病患者患甲癬的風險或患病率增加，老年人口不斷增加，對安全有效治療的需求增加，越來越重視開發新的甲癬治療方法，人們對甲癬的潛在威脅和可用治療方法的認識不斷提高預計在預測期內推動全球甲癬治療市場增長的關鍵因素。

例如，2021年4月，Alembic Pharmaceuticals Limited（Alembic）宣布其合資企業Aleor Dermaceuticals Limited（Aleor）已就艾氟康唑外用溶液提交非正式新藥申請（ANDA），用於治療腳趾甲癬. 它已獲得美國食品和藥物管理局 (FDA) 的臨時批准。

2020年10月，萌蒂推出了最新的“BETADINE”系列抗感染藥物。 這種 BETADINE EMTRIX 真菌指甲溶液可有效治療甲癬並定期使用可改善指甲外觀。

這項研究的主要特點

  • 本報告對全球甲癬治療市場進行了深入分析，顯示了以 2021 年為基準年的預測期（2022-2028 年）的市場規模（百萬美元）和復合年增長率 (CAGR) .%）。
  • 解釋了不同細分市場的潛在創收機會，並描述了針對該市場的有吸引力的投資建議矩陣。
  • 它還提供了有關市場驅動因素、制約因素、機會、新產品發布或批准、市場趨勢、區域前景、主要參與者採用的競爭戰略等方面的重要見解。
  • 全球甲癬治療市場主要參與者的概況基於以下參數，包括公司亮點、產品組合、主要亮點、財務業績和戰略。
  • 本研究涵蓋的主要公司包括 Lumenis Ltd.、Cipla Ltd.、Bayer AG、Johnson & Johnson、Moberg Pharma AB、Pfizer Inc.、Novartis、Galderma SA、Dr. Reddys Laboratories Ltd.、Medimetriks Pharmaceuticals Inc. 和 Bausch Health Companies Inc.（Valeant Pharmaceuticals Inc.）等。
  • 這份報告中的見解將使營銷人員和企業高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。我猜。
  • 《全球甲癬治療市場》報告面向該行業的各種利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和金融分析師。
  • 利益相關者可以通過用於分析全球甲癬治療市場的各種戰略矩陣來促進他們的決策。

內容

第 1 章目的和先決條件

  • 調查目的
  • 先決條件
  • 縮寫說明

第二章市場展望

  • 報告內容
    • 市場定義和範圍
  • 執行摘要
    • 市場概況：按治療類型分類
    • 市場概況：按類型分類
    • 市場概況：按地區
  • 連貫機會圖 (COM)

第 3 章市場動態、法規和趨勢分析

  • 市場動態
    • 全球甲癬患病率上升
    • 替代治療方案的可用性
    • 對安全有效的甲癬治療的需求不斷增加
  • 影響分析
  • 主要亮點
  • 監管場景
  • 產品發布/批准
  • 害蟲分析
  • 對 PORTER 的分析
  • 合併/收購場景

第 4 章全球甲癬治療市場-冠狀病毒 (COVID-19) 大流行的影響

  • COVID-19 的流行病學
  • 供應方和需求方分析
  • 經濟影響

第 5 章全球甲癬治療市場，按治療類型，2017-2028

  • 藥物治療
  • 激光治療
  • 光動力療法

第 6 章全球甲癬治療市場，按類型，2017-2028

    • 2022 年和 2028 年市場份額分析 (%)
    • Y-O-Y 增長分析，2017-2028 年
    • 細分趨勢
  • 遠端甲下甲癬的治療
    • 2017-2028 年市場規模、預測、同比增長率
  • 白色淺表甲剝離
    • 2017-2028 年市場規模和預測，同比增長率
  • 甲下近端甲癬
    • 市場規模和預測，同比增長率，2017-2028 年，
  • 其他類型
    • 市場規模和預測，同比增長率，2017-2028 年，

第 7 章 2017-2028 年按地區分列的全球甲癬治療市場

    • 2022 年和 2028 年市場份額分析 (%)
    • 2017-2028 年同比增長分析
    • 細分趨勢
  • 北美
    • 2017-2028 年按產品類型劃分的市場規模和預測，同比增長率
    • 市場規模和最終用戶預測，同比增長率，2017-2028 年
  • 歐洲
    • 2017-2028 年按產品類型劃分的市場規模和預測，同比增長率
    • 2017-2028 年市場規模和預測，同比增長率，按最終用戶分類
  • 亞太地區
    • 2017-2028 年按產品類型劃分的市場規模和預測，同比增長率
    • 2017-2028 年市場規模和預測，同比增長率，按最終用戶分類
  • 拉丁美洲
    • 市場規模和按產品類型預測，同比增長率，2017-2028 年
    • 2017-2028 年按最終用戶劃分的市場規模/預測和同比增長率
  • 中東和非洲
    • 2017-2028 年按產品類型劃分的市場規模和預測，同比增長率
    • 2017-2028 年市場規模和預測，同比增長率，按最終用戶分類
  • 世界其他地方
    • 市場規模和按產品類型預測，同比增長率，2017-2028 年
    • 2017-2028 年市場規模和最終用戶預測以及同比增長率

第八章競爭格局

  • Lumenis Ltd.
  • Cipla Ltd.
  • Bayer AG
  • Johnson & Johnson
  • Moberg Pharma AB
  • Pfizer Inc.
  • Novartis
  • Galderma SA
  • Dr. Reddys Laboratories Ltd.
  • Medimetriks Pharmaceuticals Inc.
  • Bausch Health Companies Inc.（Valeant Pharmaceuticals Inc.）

第 9 章

  • 調查方法介紹
  • 關於出版商
簡介目錄
Product Code: CMI5423

Onychomycosis is a fungal infection of the toenails or fingernails that may involve any component of the nail unit. For treatment, drugs remain the first-line treatment choice owing to a consistently high success rate. A newer generation of oral antifungal agents (itraconazole and terbinafine) has replaced older therapies in the treatment of onychomycosis.

Market Dynamics:

Risk of onychomycosis in diabetic patient or increase in prevalence of diabetes, growing geriatric population, increase in demand for safe and effective treatment, rise in focus on the development of novel onychomycosis treatments, and growing awareness among people about potential threats of onychomycosis and available treatments are major factors expected to drive growth of the global onychomycosis treatment market over the forecast period.

For instance, in April 2021, Alembic Pharmaceuticals Limited (Alembic) announced that its joint venture Aleor Dermaceuticals Limited (Aleor) received tentative approval from the U.S. Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for Efinaconazole Topical Solution for the treatment of onychomycosis in the toenail.

Moreover, in October 2020, Mundipharma launched the latest addition to its BETADINE range of infectious disease therapies. This BETADINE EMTRIX fungal nail solutions effectively treats the onychomycosis and improves the nail appearance after regular application.

Key features of the study:

  • This report provides in-depth analysis of the global onychomycosis treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global onychomycosis treatment market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Lumenis Ltd., Cipla Ltd., Bayer AG, Johnson & Johnson, Moberg Pharma AB, Pfizer Inc., Novartis, Galderma SA, Dr. Reddys Laboratories Ltd., Medimetriks Pharmaceuticals Inc., and Bausch Health Companies Inc. (Valeant Pharmaceuticals Inc.), among others.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global onychomycosis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global onychomycosis treatment market.

Detailed Segmentation:

  • Global Onychomycosis Treatment Market, By Treatment Type:
    • Drugs
    • Laser Therapy
    • Photodynamic Therapy
  • Global Onychomycosis Treatment Market, By Type:
    • Distal Subungual Onychomycosis
    • White Superficial Onychomycosis
    • Proximal Subungual Onychomycosis
    • Other Types
  • Global Onychomycosis Treatment Market, By Geography:
    • North America
    • Europe
    • Asia-Pacific
    • Middle East and Africa
    • South America
  • Company Profiles:
    • Lumenis Ltd.
    • Cipla Ltd.
    • Bayer AG
    • Johnson & Johnson
    • Moberg Pharma AB
    • Pfizer Inc.
    • Novartis
    • Galderma SA
    • Reddys Laboratories Ltd.
    • Medimetriks Pharmaceuticals Inc.
    • Bausch Health Companies Inc. (Valeant Pharmaceuticals Inc.)

Table of Contents:

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Treatment Type
    • Market Snapshot, By Type
    • Market Snapshot, By Geography
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Increasing prevalence of onychomycosis around the world
    • Availability of alternative treatment options
    • Rise in demand for safe/effective onychomycosis treatment
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product launch/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Global Onychomycosis Treatment Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Onychomycosis Treatment Market, By Treatment Type, 2017-2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Drugs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
  • Laser Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
  • Photodynamic Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)

6. Global Onychomycosis Treatment Market By Type, 2017-2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Distal Subungual Onychomycosis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
  • White Superficial Onychomycosis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
  • Proximal Subungual Onychomycosis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
  • Other Types
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)

7. Global Onychomycosis Treatment Market By Geography, 2017-2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
  • Middle East and Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
  • Rest of World
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)

8. Competitive Landscape

  • Lumenis Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Cipla Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Bayer AG
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Johnson & Johnson
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Moberg Pharma AB
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Pfizer Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Novartis
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Galderma SA
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Dr. Reddys Laboratories Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Medimetriks Pharmaceuticals Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Bausch Health Companies Inc. (Valeant Pharmaceuticals Inc.)
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Analyst Views

9. Section

  • Research Methodology
  • About us